Innate Immunity Stimulation Via TLR9 in Early AD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Innate Immunity Stimulation Via TLR9 in Early AD — Stella

Home/Mild Cognitive Impairment/

View on ClinicalTrials.gov

Recruiting

Back to Mild Cognitive Impairment trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

NYU Langone Health, New York, New York

Key details

Phase

Early testing

Sponsor

NYU Langone Health

Collaborators

Alzheimer's Association

Enrollment target

~18 participants

Started

March 2023

Primary completion

November 2026

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

60 Years – 85 Years

Last updated January 2026